Dennis M. Lanfear - 22 Jul 2024 Form 4 Insider Report for Coherus BioSciences, Inc. (CHRS)

Role
President & CEO, Director
Signature
/s/ Bryan McMichael, as Attorney-in-Fact for Dennis M. Lanfear
Issuer symbol
CHRS
Transactions as of
22 Jul 2024
Net transactions value
$0
Form type
4
Filing time
24 Jul 2024, 20:16:42 UTC
Previous filing
23 Jan 2024
Next filing
07 Jan 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CHRS Stock Option (Right to Buy) Award $0 +196,500 $0.000000 196,500 22 Jul 2024 Common Stock 196,500 $2.41 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On April 11, 2024 the Reporting Person was granted a performance stock option to purchase 982,500 shares of common stock, of which 196,500 of the shares vested and became exercisable on July 22, 2024 in connection with the Closing of the sale of Coherus BioSciences, Inc.'s YUSIMRY franchise.